Targeted cancer missile vs. immune booster: Head-to-Head fight for myeloma control

This study aims to find the better initial treatment for adults newly diagnosed with multiple myeloma who are not candidates for a stem cell transplant. It will compare two different drug combinations: one featuring a targeted 'antibody-drug conjugate' (belantamab mafodotin) and the other featuring an immunotherapy drug (daratumumab), both given with three other standard medications. The main goals are to see which combination helps more patients achieve a deep, undetectable level of cancer (minimal residual disease negativity) and keeps the cancer from growing longer.